Afivastobart
Monoclonal antibody
Also known as AB598
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Gastric Cancer · Phase 1
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ARC-25 NCT05891171 · Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC) Registry: NCT05891171 | 1 | Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) (Up to 2 years); Dose Escalation Cohorts: Number of Participants with Dose-Limiting Toxicities (DLTs) (Up to 2 years) 2027-09 | In progress: results expected 1 Sept 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
Other CD39 (ENTPD1) drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
This drug's own stage for Gastric Cancer: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Afivastobart: this drug | Phase 1 | Monoclonal antibody | CD39 (ENTPD1) | not yet graded | No reviewed efficacy summary in this indication | |
| Capecitabine | ApprovedUS marketing discontinued | Small molecule | Fluoropyrimidine (antimetabolite) | not yet graded | No reviewed efficacy summary in this indication | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Reliable signal | NCT01170663: Overall Survival Time (OS) (Randomization up to 27.5 months): Ramucirumab (IMC-1211B) Plus Paclitaxel 9.6 months (95% CI 8.5 to 10.8) | Placebo Plus Paclitaxel 7.4 months (95% CI 6.3 to 8.4) NCT00917384: Overall Survival (OS) (Randomization up to 28 months post-randomization): IMC-1121B (Ramucirumab) 5.2 months (95% CI 4.4 to 5.7) | Placebo 3.8 months (95% CI 2.8 to 4.7) | |
| Tislelizumab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Zanidatamab | Approved | Multispecific antibody | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| ASP2138 | Phase 3 | Multispecific antibody | Claudin 18.2 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Camrelizumab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Disitamab Vedotin | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| ONO-4578 | Phase 3 | Small molecule | Prostaglandin E2 receptor 4 (EP4) | Reliable signal | NCT06256328: ONO-4578-08 study (NCT06256328): median PFS 9.0 months (ONO-4578 + nivolumab + chemotherapy) vs 6.9 months (placebo + nivolumab + chemotherapy); HR 0.67, 90% CI 0.48-0.92, P=0.040. | |
| Retlirafusp Alfa | Phase 3 | Multispecific antibody | PD-L1 and TGF-beta (TGF-βRII trap) | Partial signal | NCT04950322: Primary endpoint, overall survival vs placebo plus CAPOX: median 16.8 vs 10.4 months (HR 0.53) in PD-L1 CPS >=5 and 15.8 vs 11.2 months (HR 0.66) in the ITT set (JCO, 2026-09-24). | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| S-1 | Phase 3 | Small molecule | Thymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil) | not yet graded | No reviewed efficacy summary in this indication | |
| Serplulimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Sonesitatug Vedotin | Phase 3 | Antibody–drug conjugate | Claudin 18.2 (CLDN18.2) | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| agenT-797 | Phase 2 | Cell therapy | Invariant TCR / NKG2D ligands (tumor cell recognition), no single defined myeloma antigen | not yet graded | No reviewed efficacy summary in this indication | |
| Givastomig | Phase 2 | Multispecific antibody | Claudin 18.2 (CLDN18.2) x 4-1BB | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-A1904 | Phase 2 | Antibody–drug conjugate | Claudin 18.2 (CLDN18.2) | not yet graded | No reviewed efficacy summary in this indication | |
| ASP546C | Phase 1/2(overall) | Antibody–drug conjugate | Claudin 18.2 (CLDN18.2) | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-921 | Phase 1/2 | Antibody–drug conjugate | — | not yet graded | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Afivastobart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.